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Abstract
Breast cancer (BC) is a global public health burden, constituting the highest 
cancer incidence in women worldwide. Connexins 43 proteins propagate intercellu-
lar communication, gap junction intercellular communication (GJIC), remarkably 
expressed in several tumor types including liver, prostate, and breast. This domain 
of Cx43 possesses functionally critical sites identical to those involved in gating of 
channel and phosphorylation sites for various kinases. However, the mechanism 
by which Cx43 down regulation occurs in breast cancer is far from clear. Several 
mechanisms like Cx43 promoter hyper-methylation or a cancer-specific reduction 
of Cx43 expression/trafficking by the modulation of various components of the 
Cx43 life cycle give the idea to be involved in the down regulation of Connexins in 
mammary glands, but irreversible mutational alterations have not yet been proved 
to be among them. Summarily, the efficacy or specificity of these drugs can be 
increased by a combinatory approach considering an effect on both the Connexins 
and their regulatory molecules. This chapter will summarize the knowledge about 
the connexins and gap junction activities in breast cancer highlighting the differ-
ential expression and functional dynamics of connexins in the pathogenesis of the 
disease.
Keywords: Breast Cancer, Connexin, Tumor Suppressor, Gap junction,  
mammary gland
1. Introduction
Cancers that originate from the breast tissue are called as Breast cancers. Quite 
often, these cancers originate from the epithelial cells lining the milk ducts or 
lobules supplying the ducts with milk [1]. Sub-classification of breast cancer into 
various types is done on the basis of certain characteristics that the cancers develop 
depending on their origin i.e. whether cancer originates from glandular portion 
or ductal portion of the breast. Accordingly, cancers that stem from lobules are 
called as lobular carcinomas, whereas those stemming from ducts are called as 
ductal carcinomas. Once Primary tumors become invasive, it spreads beyond its 
place of origin (Breast) to the regional lymph nodes. It may also metastasize i.e., 
expand to different organ systems of the body, thereby becoming systemic in 
nature. On the basis of this expansion, breast cancer is of two types Non-invasive or 
in-situ and invasive. A non-invasive or in-situ cancer is one where the cancer cells 
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remain confined to boundaries of the lobular unit or draining duct of their origin. 
On the other hand, cancer cells that traverse outside the basement membrane of 
the lobules or ducts into the surrounding normal tissues are classified as invasive 
cancers. Apart from these, there are other types of breast cancer with different 
stages, varied aggressiveness and different genetic makeup. These factors greatly 
affect the chances of survival of a patient. Several breast cancers are up regulated 
by estrogens. These cancer cells carry estrogen receptors on their surfaces and are 
called Estrogen Receptor-positive cancers or ER-positive cancers. Similarly, some 
women suffer from another type of breast cancer called as HER2-positive breast 
cancer. HER2 is a gene responsible for cell growth, division and repair. Increased 
copy number of HER2 gene may result in faster growth of cancers. Women with 
HER2-positive breast cancer have higher incidence of disease recurrence making it 
as a risk factor for breast cancer recurrence. The disease is also more aggressive than 
women who do not have this type of breast cancer.
2. Stages of breast cancer
Expansion of a cancer determines its stage. Stages of a cancer indicate whether 
the cancer is limited to the area of origin or has spread to other healthy tissues of the 
body. Four important characteristics determine a cancer stage:
a. Size of the cancer.
b. Type of cancer i.e. invasive or non-invasive.
c. Has cancer reached lymph nodes,
d. Has cancer metastasized to other body parts.
Firstly, on the basis of extent of the cancer, it can be classified as local, regional 
or distant. A cancer is local, when it is confined within the breast (where it origi-
nated). It is regional when lymph nodes are involved. And it is distant when it has 
metastasized to other body parts as well.
There is another staging system used to describe the cancer called as TNM 
staging system. The TNM System is based on three components - size of the tumor 
(denoted by T), involvement of the lymph node (denoted by N) and whether the 
cancer has metastasized (denoted by M).
Stage 0: It is a non-invasive stage, during this stage cancer is present at its origin 
e.g., Ductal Carcinoma In Situ (DCIS). There is no indication of the cancer cells or 
non-cancerous abnormal cells traveling beyond their origin to neighboring normal 
tissues.
Stage I: This stage describes an invasive breast cancer i.e., cancer cells invade 
neighboring normal tissues. There are chances of microscopic invasion in this 
stage. In such an invasion, the cancer cells have just begun to travel outside the 
boundaries of their duct or lobule. However, the invading cancer cells are not more 
than 1 mm.
Stage II: This stage is further sub-categorized into stages IIA and IIB, both 
describing a different invasive breast cancer. Stage IIA refers to an invasive breast 
cancer where the tumor cannot be located in the breast but lymph nodes (axillary) 
under the arm show presence of cancer cells.
Stage IIB: Refers to an invasive breast cancer where a tumor sized between 2 cm 
and 5 cm has spread to axillary lymph nodes.
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Stage III: This stage is further sub-categorized into three stages - Stages IIIA, 
IIIB and IIIC. Stage IIIA refers to an invasive breast cancer where either the tumor 
cannot be located in the breast but cancer is found in axillary lymph nodes which 
are clumped or clinged to other structures, or lymph nodes at breast bone may be 
involved too.
Stage IIIB: Defines an invasive breast cancer stage where cancer has involved 
chest wall or breast skin or both and may involve axillary lymph nodes and showing 
Stage IIIA like features too.
Stage IIIC: Refers to an invasive breast cancer where there is no evidence of 
cancer in the breast or, in the event there exists a tumor, it is of any size, which 
may be involving chest wall or breast skin, or both. In this stage, the cancer has 
also extended to the lymph nodes below or above the collarbone and may also have 
spread to axillary lymph nodes or to lymph nodes near the breastbone.
Stage IV: This stage describes an invasive breast cancer which has extended 
outside the breast and adjacent lymph nodes and has affected other organs of the 
body e.g., lungs, bones, brain, liver, skin etc.
3. Epidemiology of breast cancer
In Modern world, occurrence of non-communicable diseases is increasing day by 
day [2, 3]. This is mainly due to factors like increased lifespan, prolonged exposure 
to risk factors and changes in lifestyle. While being one of the most crucial diseases 
in the world, cancer is also regarded as a complicated-on account of being multi-
factorial, epidemiologically. In 2012 alone, around 14.9 million new cases of cancer 
were tradition, culture, food habits, intra-community marriages and ethnicity. In 
recent past recorded. It is estimated that in the next two decades, this number will 
be around 22 million [4]. Now a day, breast cancer is becoming more common in 
women and is cosmopolitan in nature with high rate of incidence [5]. It accounts for 
25% of all types of cancers, recording 1.7 million new cases per year. It is also the 
second common most cancer [4]. As per WHO, the latest incidence rate of breast 
cancer in east Africa to west Europe ranges from 19.4 to 89.7 per one lakh people 
respectively [6]. Other than its fast growth rate in South America and Africa, 
breast cancer incidence in on rise in several Asian countries too. For instance, Japan 
witnessed a 6% increase per year from 1999 to 2008. In Australia, mortality rate 
due to breast cancer has reduced by 2%. While it is increasing in several countries. 
Malaysia and Thailand recorded the highest increase. The ratio of mortality and 
incidence of breast cancer in the world and Asia-Pacific countries is 0.30 and 0.27 
respectively. However, this ratio of mortality and breast cancer incidence is 0.2 and 
0.41 in the Pacific and Southeast-Asian countries respectively [7]. Not so long ago, 
breast cancer incidence was rare in South Korea. However, now, the incidence and 
death rate from breast cancer has increased [8]. Hong Kong has seen a decline in 
the incidence [9]. Generally, different regions show different breast cancer inci-
dence due to difference in risk factors, level of education, different life expectancy, 
screening programs [10], and cancer registration [2]. The number of diagnosed 
breast cancer cases is increasing because of the increased life expectancy and 
increased full health screens [10]. Cancer accounts for around 3–4 million deaths 
worldwide annually. Of these, 2–3 million deaths occur in developing countries 
[11]. In India, cervical cancer has a higher occurrence than breast cancer. On the 
contrary, our state (J&K) in the Indian Subcontinent, Kashmir shows a reverse 
trend (World Health Organization, 1978) (Figure 1). Rise in breast cancer in 
Kashmir valley is considered a major health concern. Experts attribute this increase 
in breast cancer to various factors like sedentary lifestyle, bottle feeding, late 
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marriages etc. Kashmir valley is quite different from other areas with respect to its 
unique geographical location, Kashmir has seen a huge increase in the occurrence of 
breast cancer among its unexplored ethnic population. The overall cancer incidence 
in Kashmir region is increasing. In men, esophagus and gastroesophageal (GE) 
junction, lung, stomach, colon, rectum, lymph nodes, skin, laryngopharynx, blood, 
prostate and brain are the common sites of cancer. While in females the common 
sites are breast, esophagus and GE junction, ovary, colon, rectum, stomach, lung, 
gallbladder, lymph nodes, blood and brain.
4. Connexin 43 and breast cancer
Connexin 43 is the most widely expressed gap-junction protein in normal breast 
tissue and is thought to play important role in normal mammogenesis, lactogenesis 
and involution [13]. Cx43 is not expressed in normal breast stem cells but is 
expressed in the normal breast epithelial cells derived from these breast stem cells 
[14–16]. Studies have shown that Cx43 is down regulated at the mRNA and protein 
level in human breast tumors and several human mammary tumor cell lines [17]. 
Decreased expression of connexin gap junctions is seen in breast cancer at various 
stages of progression and restoration of gap-junction intercellular communication. 
Studies have shown that Cx43 is down regulated at the mRNA and protein level in 
human breast tumors and several human mammary tumor cell lines [17]. Decreased 
expression of connexin gap junctions is seen in breast cancer at various stages of 
progression and restoration of gap-junction intercellular communication. Under in 
vitro conditions it has been seen that the upregulation of connexins restore normal 
phenotype and reduce tumor growth in vivo conditions [18, 19]. Various studies 
have shown that down-regulation of Cx43 plays role in primary tumor formation as 
well as its metastasis in breast tissue. Primary breast cancer is generally composed 
of tumor cells and surrounding connective tissue. The arrangement within cancer 
creates multiple patterns of cell–cell interactions among tumor cells and between 
tumor cells and normal neighboring stromal cells. Among, these patterns the GJIC 
involving Cx43 is considered to be initial step associated with malignant cell 
transformation. Studies have shown down-regulation of Connexin 43 gap-junction 
occurs in human breast cancer tissues compared with the non-neoplastic breast 
tissue surrounding primary tissue. It has been seen that re-expression of Cx43 
Figure 1. 
Shows year-wise number of registered cancer patients, incidence sites and cancer trends 2000–2012). Adapted 
from Wani [12].
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reverses the malignancy of human mammary carcinoma cells [19–21]. In, rat 
mammary carcinoma induced by DMBA data obtained demonstrates that connexin 
43 gap junction loss is a common feature of transformed mammary neoplastic cells. 
Furthermore, data obtained with rat mammary carcinoma, induced by DMBA also 
demonstrates that the loss of connexin 43 gap junction is a common feature of 
mammary neoplastic transformed cells. In human mammary carcinoma 
(MDA-MB-435) cells it has observed that the Cx43 re-expression suppresses the 
cancer phenotype, increases ability of cells to differentiate into well defined 3D 
structures and also reduces the tumor growth in animal models [20, 22]. Studies 
have also shown that down-regulation of endogenous connexin 43 expression by 
small interfering RNA promoted a more aggressive phenotype in human breast 
cancer cell lines. It was seen in this study that Cx43 reduced the expression of 
fibroblastic factor receptor (FGFR) and of other proteins that are involved in tumor 
progression. Studies have revealed that over expression of Cx43 in tumor cells not 
only restores growth control, but they also revert to less malignant phenotypes [18]. 
Upregulation of Cx43 by the drugs like genistein and quercetin leads to GJIC-
independent inhibition of cell proliferation [23]. Cx43 plays role in tumorigenesis 
probably by inhibiting angiogenesis independently of cell communication as 
inhibition of Cx43 expression by RNAi in breast cancer Hs578t cells, resulted in 
faster growth and increased aggressiveness of the cells, TSP-1 expression was 
reduced while pro-angiogenic factor VEGF was upregulated. Similar results were 
observed in MDA-MB-231 cells over expressing Cx43. In addition conditioned 
media from these cells inhibited in vitro endothelial cell tubulogenesis and migra-
tion [24]. Additionally, tumor angiogenesis was decreased in xenografts of Cx43-
overexpressing MDA-MB-231 cells. Altogether these findings suggest that Cx43 
plays tumor suppressing role by mediating cell proliferation, migration and angio-
genesis, enduring support to relatedness between physiological variation in Cx43 
levels and aggressive of breast cancer. Tumor metastasis, a multi-step process 
involves the entry of transformed cells into the circulation after dissociating from 
the site of origin, extravasation from the vascular system and proliferation into 
tumor masses at secondary tissue sites. Different stages of this metastatic cascade 
depend both on cell–cell and cell-matrix interactions [25]. Metastasis has been 
shown to be promoted by down-regulation of connexins as the breast metastasis 
suppressor 1 gene exogenous expression in MDA-MB-435 cells led to upregulation 
of Cx43 and restoration of GJIC, providing evidence that connexins act as tumor 
suppressors in metastasis [26]. The migratory potential and ability to invade 
through basement membrane matrix was found to diminish in cells with exogenous 
expression of Cx26 and Cx43 during functional in vitro studies [27] along with a 
slight drop-off in matrix metalloproteinase activity [28]. Additionally, studies show 
decrease in the number of metastases to lungs in mice injected with breast cancer 
cells expressing Cx43 relative to mice injected with vector controls only [20]. The 
movement of cancer cells across the endothelial cell barrier as they move in and out 
of the blood vessels has been shown to be a key step in metastasis and studies have 
shown that Connexins play an important role in tumor cell vascular intravasation 
and extravasation [29]. Co-culturing of endothelial cells with breast cancer cells 
results in the reduction of GJIC in endothelial cells. This reduction weakens cell–cell 
contacts and also it becomes easier for cells to cross endothelial barrier during the 
process of extravasation and intravasation [30]. This fact was supported by another 
study which shows that over expression of Cx43 in HBL-100 breast cancer cells 
(GJIC deficient) makes them capable of forming heterocellular junctions. These 
junctions allow dye transfer between human microvascular endothelial cell express-
ing cx43 and breast cancer cells resulting in tumor cell diapedesis. Treatment of 
endothelial culture with GJIC inhibitors or co culturing of endothelial cells with 
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breast cancer cells that express mutated or non-functional Cx43 results in blockage 
of trans endothelial migration [31]. Hence these studies imply that both homocel-
lular GJIC between endothelial cells and heterocellular GJIC between endothelial 
cells and breast cancer cells facilitate trans endothelial migration. A series of studies 
performed on the effects of metastatic breast cancer cells on osteoblast differentia-
tion with MDA-MB-231 and MC3T3-E1 cells showed inhibition of osteoblast 
differentiation by conditioned medium from breast cancer cells [32, 33]. It has also 
been demonstrated by other studies that in MDA-MB-231 Cx43 expression results in 
decreased expression of OB-cadherin [34] a similar trend was also found in Cx43 
expressing MDA-MB-435 cells. Decrease in the expression of N-cadherin, a protein 
which is involved in increased motility, invasion and metastases of breast cancer 
cells [35, 36] has been observed in in Cx43 over expressing MDA-MB-231 cells [34] 
this clearly shows that it contributes to decreased metastasis in vivo. In human 
glioblastoma cells it has been seen that Cx43 enhances response to chemotherapeu-
tic agents or low serum hence confirming the fact that Cx43 shows anti metastatic 
effect [37]. In human breast cancer tissue, studies have also demonstrated that 
expression of Cx43 is directly correlated with the expression of BAK (Bcl-2 homolo-
gous antagonist/killer), a pro-apoptotic gene of the Bcl-2 family [38]. In human 
mammary carcinoma cell, MDA-MB-435 Cx43 suppressed the cancer phenotype 
and cell growth in culture and in animal models. There remains little doubt that 
down regulation of Cx43 plays a very important role in the primary tumor forma-
tion and its metastasis in mammary glands. However, the mechanism by which 
Cx43 down regulation occurs in breast cancer is far from clear. Several mechanisms 
like Cx43 promoter hyper-methylation or a cancer-specific reduction of Cx43 
expression/trafficking by the modulation of various components of the Cx43 life 
cycle appear to be involved in the down regulation of Connexins in mammary 
glands, but irreversible mutational alterations have not yet been proved to be among 
them. Therefore, the role of Cx43 in carcinogenesis requires further investigations. 
Additional studies on Cx43 in different cancers, thus, will establish its role in cancer 
signaling and thus as a therapeutic target.
5.  Regulation of Connexin 43 by epigenetic mechanisms and 
transcription factors
Tumors and transformed cell lines generally exhibit down regulation of 
Connexin expression. This down regulation is said to be responsible for the loss of 
proliferating control. However, deletion or mutation of connexin gene as a com-
mon factor in human tumors has not yet been demonstrated by various intensive 
studies on the subject. On the other hand, what various studies have shown is that 
silencing of Connexin expression in several kinds of malignant cells can be caused 
due to epigenetic inactivation of the promoter region by hypermethylation. Studies 
have also indicated that types of cells and connexins determine the effects of DNA 
methyltransferase inhibitors on connexin expression, as illustrated by Vinekn et 
al. in a review [39]. A correlation was established with micrometastasis into lymph 
nodes and the lack of Cx43 mRNA expression in adjacent normal lung cancer tissue 
in human non-small lung cancers [40]. Patients lacking Cx43 mRNA possessed 
higher frequency of promoter methylation compared with Cx43 mRNA-positive 
patients, as reported by Chen. Their data also indicates a possible interference of 
promoter methylation with AP-1 binding to the promoter which results in lack 
of Cx43 gene expression. The human Cx43 proximal promoters possesses several 
binding sides for Sp1 and AP1 transcription factors and have been demonstrated 
to be indispensable for optimal promoter activity by promoter/report assays and 
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Sp1/AP1 over expression studies. The Sp1- and Ap1- binding sites were shown to 
contribute to the activity of the promoter. Each of them also contributed to bind the 
transcription factors Sp1/Sp3 or AP1, respectively. Both Sp1 and Sp3 resulted in the 
rat Cx43 promoter activation during trans-activation assays. These findings indicate 
the importance of the transcription factors Sp1, Sp3 and AP1 in rat Cx43 proximal 
promoter activity. Cell type-specific expression of Cx43 may thus depend on 
additional activators or repressors in different Cx43-expressing cell types (includ-
ing cardiomyocytes) as similarities exist in proximal promoter regulation by univer-
sally expressed transcription factors (Sp1, Sp3, AP1). Although the mechanism 
Connexin gene silencing by DNA methylation is clear, the origin of this epigenetic 
modification still remains elusive. In liver cancer, elevated DNMT1 mRNA levels 
are thought to decrease expression of connexins, in casu Cx26 [41]. Moreover, the 
aberrant binding of transcription factors to methylated Connexin gene promoters 
may contribute to poor Connexin expression in cancer cells. This is supported by 
the decreased Cx43 gene transcription accompanied by DNA methylation in human 
non-small cell lung cancer cells. The decreased Cx43 gene transcription is also 
correlated with reduced binding of activator protein 1 (AP1) to its promoter [40]. 
Furthermore, in human breast cancer cells [42] and rat liver cancer cells [43] the 
Sp1 cis-acting elements of the Cx26 and the Cx32 gene promoter are especially rich 
in methylated CpG dinucleotides.
6. Regulation of Connexin 43 by micro RNAs
Almost one-tenth of all new cancers and 23% of cancer cases detected in females 
are breast carcinomas with more than 1 million diagnoses every year worldwide 
[44, 45]. Major causes of this disease-related death are relapse and metastasis [46, 
47]. Recent studies that on the metastatic mechanisms of breast cancer suggest the 
gap junction to be a major regulator of tumor metastasis [48]. Located at the cell 
membrane, the gap junction primarily comprises of different connexin proteins. 
These connexin proteins are closely associated with numerous functions of the cell 
[49, 50]. Connexins constitute a family of 21 members with Cx43 being abundantly 
expressed in the mammary gland [49]. It is reported that Cx43 plays an important 
role in normal cell migration [51] and tumor cell invasion [52]. As such, promis-
ing strategies in regulating cell functions are provided by the regulation of Cx43 
expression [53, 54]. Different transcription factors tightly regulate the expression 
of CX43 gene at transcription level. Studies have found that Sp1 (specificity protein 
1), Sp3, AP-1 (activating protein 1) and c-Jun can promote transcriptional activity 
of Cx43 gene by directly binding to its promoter [55, 54] addition, at the post-
transcription level Cx43 is also closely regulated by miRNAs [53, 56, 57]. miRNAs, 
largest groups of posttranscriptional regulators, [58]. Eight bases at the 5′end of 
miRNAs, are involved in posttranscriptional regulation. These two to eight bases 
could bind to the 3′-UTR of the target genes in order to bring about inhibition of 
gene expression at mRNA level [58]. By virtue of their direct or indirect regulation 
of target gene expression, miRNAs regulate a number of biological processes. The 
processes include cell cycle [59], growth [60], apoptosis [60], differentiation [61] 
and stress reaction [62]. Studies have identified miR-1, miR-206, and miR-381 as 
potent suppressors of Cx43 [53, 56, 63]. Cx43 has been found to enhance metastasis 
in breast cancer cells. It has been proven to be a direct negative target for miR-206, 
miR-1 and miR-133 and an indirect target for miR 381 [8]. During the myoblast 
differentiation in vitro and in vivo, two related miRNAs, miR-206 and miR-1, 
cause inhibition of Cx43 protein expression without altering Cx43 mRNA levels 
[63]. Further it has been reported by Anderson et al. that Cx43 mRNA contains 
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two binding sites in its 3’UTR for miR-206/miR-1, both of which are essential for 
an efficient down regulation. Also, they observed sections of eight nucleotides in 
the 3’UTR of Cx43 gene that are complementary to the first eight nucleotides from 
the 5′ end of miR-1. Which then they proved that miR-1 binds to these nucleotide 
sequences. miR-1 was also shown to cause reduction of Cx43 levels in isolated 
neonatal rat ventricular myocytes in culture [64]. They further found two putative 
target sequences in the 3′ UTR of Cx43 for miR-206 and proved that miR-206 that is 
expressed ectopically binds these sites. Moreover, the ectopic expression of miR-
206 downregulated the endogenous expression Cx43 gene without affecting Cx43 
mRNA expression. The continuous expression of miR-206 in osteoblasts resulted 
in decreased expression of osteoblast differentiation and Cx43 protein expression. 
The suppression of Cx43 gene expression was caused by miR-381 via the promoter 
region −500/−250 miR-381 could directly bind the sequences CACUUGUAU in 
the 3′UTR. Site-directed gene mutation was done (CCAAT/enhancer-binding 
protein α) in order to inhibit C/EBPα expression. By binding it to a canonic element 
(AATTGTC) located at −459/−453 in the promoter region of the Cx43 gene, they 
identified C/EBPα as a novel transcription factor. Therefore, miR-381 causes C/
EBPα dependent Cx43 suppression in breast cancer cells.
7. IRES mediated regulation of Connexin 43
Connexin 43 (Cx43) is one of the main gap junction (cell–cell channel) proteins 
expressed in the heart ventricle. Constitutive expression of Connexin 43 has been 
found to be responsible for the anisotropic propagation of action potentials in the 
heart [65]. And also, Cx43 gap junctions are essential for the synchronous contrac-
tion of the myometrium of the uterus during labour pain. While the expression of 
Cx43 is ordinarily sparse in the myometrium, the ovarian hormones and mechani-
cal stretch upregulate it [66]. This upregulation is seen at the transcriptional as well 
as the translational level, as there is accumulation of Cx43 mRNA before the swift 
advent of Cx43 protein, just prior to childbirth [67–70]. The Cx43 gene like most of 
the connexin genes consists of two exons separated by a large intron. Exon 1 con-
tains most of the 5P-untranslated region (5P-Utr) while the remaining 13 bases of 
the 5P-UTR followed by the entire coding region and the 3P-UTR are contained in 
Exon 2. There is wide acceptance of observation that in eukaryotes, protein synthe-
sis initiation begins with the binding of the small ribosomal subunit to the 5P-cap 
structure. Then the mRNA is scanned by the 40S ribosome until it encounters 
an AUG codon where the 60S ribosomal subunit joins, and hence the translation 
begins. Between the cap structure and the first AUG codon, most cellular mRNAs 
contain fewer than 50 nt between the cap structure and the first AUG codon but 
the 5P-UTR of Cx43 mRNA has been found to 208 nt. In addition, the 5P-UTR of 
Cx43 mRNA has a stable secondary structure. The scanning of the 40S ribosome 
can be inhibited by such structures. The secondary structures of the Cx43 IRES and 
most of the other described IRES elements have a semi-conserved Y-like structure, 
which is suggested to have role in the IRES mediated translation in eukaryotic cells 
in Stress conditions. Inhibition of cap-dependent translation is one of the cellular 
responses to stress [71]. This inhibition allows continuation of synthesis of proteins 
essential for survival and stops the synthesis of non-essential proteins. Illustrations 
for this are as follows: VEGF is translated in response to hypoxia [72], the transla-
tion of the chaperone proteins Bip [73] and hsp70 takes place under conditions of 
cellular stress in response to misfolded and degraded proteins and in the infarcted 
myocardium FGF-2 functions in the salvage of cells [74]. In all these genes, IRES 
elements have been found that are translated even under stress conditions. The need 
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is to maintain intercellular communication via Cx43 channels even under certain 
stressful conditions likely. For instance, in the hypoxic hear gap junctional remodel-
ing occurs [75] requiring the synthesis of new Cx43. Recent reports have claimed 
that in addition to estrogen, mechanical stretch is required to upregulate expression 
of Cx43 in the uterus at the commencement of labor [66]. The fetus grows faster 
than the uterus during the later phase of pregnancy which causes physical stretch 
in the myometrium. As such, Cx43 must be speedily upregulated during this time. 
A mechanism by which a high level of translation can be accomplished during this 
stress may be offered by the IRES.
8. Carboxy terminal domain of Connexin 43 and human breast cancer
Cellular communication is paramount for tissue/organ homeostasis in multicel-
lular organisms. Exchange of small ions, secondary messengers and small metabo-
lites required for electrical and bio-chemical coupling between cells is mediated 
via intercellular channels known as gap junctions [76, 77]. Each gap junction is 
formed by association of Connexin proteins. Human genome contains 21 different 
Connexin genes, expressed differentially in various types of cells and tissues [78]. 
Among these gap junction proteins, connexin 43 (Cx43) is major gap junction pro-
tein which is widely expressed across tissues and besides its role in mediating cell 
to cell communication, it also plays very critical role in cellular proliferation [79]. 
More precisely, Cx43 acts a tumor suppressor [80] usually downregulated in various 
diseases such as cancer [81, 82], connexin 43 possesses long cytosolic C-terminus 
and most of the non-canonical functions of connexin 43 are attributed to it [83] 
(Figure 2).
More interestingly independent of full length Cx43, CT-Cx43 expression has 
been found to occur in various cell types [85]. This CT domain is subjected to 
various post translational modifications like phosphorylation, S-nitrosylation and 
Figure 2. 
Gap junctional intercellular communication (GJC) mediated by connexin proteins. Hexameric arrangements 
of connexin monomers comprise a hemi-channel or connexon. Adjoining cells each contribute one connexon 
to form a complete gap junction channel. For several connexin types, the assembly, gating and turnover of this 
channel are regulated to a large extent via phosphorylation of the cytoplasmic tail by various cellular kinases 
including: Src, PKC and MAPK. Adapted from (king and Bertram, 2005) [84].
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truncation [86]. Also CT-Cx43 has been shown to interact directly and indirectly 
with microtubules and actin respectively. The later takes place by the interaction 
of CT-Cx43 with adaptor proteins such as zonula occludens-1 (ZO-1) and drebrin 
(developmentally regulated brain protein). Perturbation of this interaction has 
been implicated for the development of various developmental and cardiac defects 
(Figure 3) [87].
The growth suppressing effect of Cx43 was not compromised while express-
ing only CT-Cx-43 in HeLa cells [89] and HEK-293 cells [89]. CT-Cx-43 has been 
shown to have nuclear localization implying that it may be involved in regulating 
gene expression directly or indirectly within the nucleus [89]. In direct regulation 
it may act as a transcriptional activator or repressor of target genes however, in 
indirect regulation it may regulate target gene by acting as a transcriptional activa-
tor or repressor of miRNAs targeting them. In various cancers it has been shown 
the expression of one tumor suppressor gene can rescue the expression of other 
tumor suppressor gene as well [75, 90]. However the exact mechanism is not fully 
understood. P53 known to act as guardian of genome is a tumor suppressor play-
ing very important role in regulating cellular process [91] such as cell proliferation 
[92, 93]. The expression of p53 increases under stress conditions [94] than its basal 
levels under normal condition [95]. These stress conditions include DNA damage 
[96] and oncogenic insults [97]. Dysregulation of p53 is considered to be initiator of 
tumorigenesis which includes its down regulation or mutation [98–100]. Expression 
of p53 has been found to be upregulated by CT-Cx43 in cardiomyocytes [88]. In 
addition, a group of small RNAs, i.e., microRNAs (miRNAs), has been shown to be 
able to regulate the expression of genes implicated in various normal and pathologi-
cal conditions, including cellular proliferation and cancer [101–106]. More precisely 
a conserved homolog of C. elegans miRNA lin-4 namely miR-125b has been found 
to be dysregulated in various cancers [107]. The expressional studies of miR-125b 
in various cancers have revealed that miR-125b is upregulated in some cancers and 
Figure 3. 
Channel dependent and independent mechanisms by which Connexin expression can alter other genes. (A) 
Channel dependent mechanism. In this model, signaling molecules (red arrow) are directly exchanged between 
cell cytoplasms there by coordinately regulating gene expression patterns in the nucleus (N) (B) connexin 
dependent but channel independent mechanism. In this model connexins that may or may not be at junction 
membrane either bind a molecule with transcriptional activity (purple trapezoid) or can cleave such a portion 
of carboxy terminus to signal to the nucleus In this model connexins that may or may not be at junction 
membrane either bind a molecule with transcriptional activity (purple trapezoid) or can cleave such a portion 
of carboxy terminus to signal to the nucleus. Adapted from (Kardami et al., 2007) [88].
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downregulated in others such as breast cancer. Therefore, it has occasionally been 
labeled as a tumor suppressor. Most of the dysregulated miRNAs has been shown to 
target tumor suppressor genes such as PTEN, RB, Cx43 and p53 [108, 109].
9. Connexin 43 as theurapatic target
Connexins have a dynamic role in the metastatic process, involving multiple 
factors. Metastasis is preceded by a series of events -tumor cells leave the primary 
tumor, move too far off sites and some start secondary tumors. While dealing with 
therapeutic issues, this variety of roles of connexins and GJIC in tumor develop-
ment requires special attention. The anti-tumor growth function of connexins and 
their observed loss in cancer has made it clear that a possible strategy to inhibit 
tumor growth could be provided by restoring connexins expression. The targets of 
anti-cancer therapeutics are enzymes that affect global gene expression including 
HDAC, a set of enzymes involved in chromatin remodeling. Upon generation and 
testing of many HDAC inhibitors (HDACi), it has been observed that the effects of 
these drugs (at least some part of them) are GJIC-dependent. When prostate cancer 
cells were treated with the HDACi Trichostatin A (TSA) restoration of both Cx43 
expression and GJIC takes place [110]. Hyperphosphorylation and degradation of 
Cx43 was also countered via the modulation of MAP kinases and Src [111]. Proteins 
that are involved in tumor progression and metastasis can regulate Connexin 
expression at transcriptional level. Cx43 is transcriptionally upregulated by the 
Ras–Raf-MAPK pathway via the interaction of its promoter with a protein complex 
that contains both HSP90 and c-Myc [112]. Protein AML1-ETO fusion protein tran-
scriptionally upregulated Cx43 expression resulting from the chromosomal trans-
location t(8;21) frequently associated with acute myeloid leukemia (AML) via the 
JNK signaling pathway. The JNK specific inhibitor SP600125 was shown to inhibit 
this effect [55]. Melanoma metastasis was promoted by the protease-activated 
receptor-1 (PAR-1) via transcriptional regulation of Cx43 [54, 113]. The importance 
of Connexin phosphorylation, especially Cx43, in the regulation of their levels and 
functions has been extensively investigated [114]. The stability and degradation 
of Connexin proteins are regulated by the lysosomal and proteasomal systems, 
in addition to phosphorylation [113]. The efficacy of drugs could be improved by 
the stabilization of the Cx43 protein. For example, while sensitizing cells to the 
pro-apoptotic effect of MG132, the rate of degradation was decreased by treatment 
with the proteasome inhibitor MG132 [115]. A major regulatory event in the life of 
Connexins is phosphorylation by the kinase Src. Phosphorylation by Src takes place 
either directly or via signaling intermediates such as PKC and MAPK which resuls 
in a disruption of GJIC [116]. This effect has been shown to lead to drug resistance 
[117]. In colon cancer cells that already express Cx43 mRNA, Cx43 expression and 
phosphorylation were enhanced by Kaempferol, a plant flavonoid, via a Stat3-
dependent mechanism. However, Kaempferol showed no effect in cells that were 
devoid of Cx43 mRNA and deficient in GJIC [118]. Therefore, targeting the post-
translational modification of connexins is limited by the requirement of a func-
tional transcriptional regulation. Such an isolated treatment would not be useful 
unless in combination with other treatments such as methylation- or acetylation-
modulatory agents in order to unblock the transcription of c bvonnexins. In ovarian 
cancer cells, Cx43 phosphorylation and inhibition of GJIC was brought about by 
their treatment with endothelin-1 (ET-1), a ligand for the ETA receptor (ETAR), 
which is overexpressed in ovarian carcinoma [119]. The selective ETAR antagonist 
BQ 123, the tyrosine kinase inhibitor tyrphostin 25 or the c-Src inhibitor 4-amino-
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effect, which suggests a role for Src in this mechanism [119]. Further, inhibition of 
ovarian tumor growth in vivo alongside a reduction of Cx43 phosphorylation was 
caused by ABT-627, an ETAR antagonist [119]. Summarily, the efficacy or specificity 
of these drugs can be increased by a combinatory approach considering an effect on 
both the Connexins and their regulatory molecules. In conclusion, gap junctional 
intercellular communication mediated by Connexins offer immense therapeutic 
opportunities that are still widely open. This approach is supported by original tools 
in the form of new findings regarding the regulation of Connexins expression. In 
view of the vast array of data about Connexins generated in various different tumor 
models and contexts, it is perhaps the right time for a consensus meeting devoted to 
focusing attention of the possibilities for Connexins as therapeutic targets.
© 2021 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
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